Bicycle Therapeutics Ltd Market Cap ($182.35 Million)
Market Cap & Net Worth: Bicycle Therapeutics Ltd (BCYC)
Bicycle Therapeutics Ltd market cap. Bicycle Therapeutics Ltd (NASDAQ:BCYC) has a market capitalization of $182.35 Million ($182.35 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16710 globally and #3981 in its home market, demonstrating a 1.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bicycle Therapeutics Ltd's stock price $3.62 by its total outstanding shares 50373281 (50.37 Million). Also see BCYC cash generation efficiency for how efficiently the company converts equity into cash flow.
Bicycle Therapeutics Ltd Market Cap History (2019–2026)
Bicycle Therapeutics Ltd market cap history from 2019 to 2026. Data shows change from $475.02 Million to $182.35 Million (-14.86% CAGR). Check Bicycle Therapeutics Ltd stock price for real-time trading data and today's change.
Index Memberships
Bicycle Therapeutics Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.01% | #452 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1640 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #224 of 263 |
Weight: Bicycle Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bicycle Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bicycle Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Bicycle Therapeutics Ltd equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
4.91x
Bicycle Therapeutics Ltd's market cap is 4.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $475.02 Million | $13.80 Million | -$30.61 Million | 34.42x | N/A |
| 2020 | $904.20 Million | $10.39 Million | -$51.01 Million | 87.03x | N/A |
| 2021 | $3.07 Billion | $11.70 Million | -$66.82 Million | 262.14x | N/A |
| 2022 | $1.49 Billion | $14.46 Million | -$112.72 Million | 103.09x | N/A |
| 2023 | $910.75 Million | $26.98 Million | -$180.66 Million | 33.76x | N/A |
| 2024 | $705.23 Million | $35.27 Million | -$169.03 Million | 19.99x | N/A |
| 2025 | $356.64 Million | $72.59 Million | -$218.96 Million | 4.91x | N/A |
Competitor Companies of BCYC by Market Capitalization
Companies near Bicycle Therapeutics Ltd in the global market cap rankings as of November 4, 2026. Also see BCYC asset base for a full breakdown of the balance sheet.
Key companies related to Bicycle Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Bicycle Therapeutics Ltd (2019–2026)
Market capitalization of Bicycle Therapeutics Ltd from 2019 to today. Between 2019 and today, Bicycle Therapeutics Ltd's market cap moved from $475.02 Million to $ 182.35 Million, with a yearly change of -14.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $182.35 Million | -48.87% |
| 2025 | $356.64 Million | -49.43% |
| 2024 | $705.23 Million | -22.57% |
| 2023 | $910.75 Million | -38.92% |
| 2022 | $1.49 Billion | -51.37% |
| 2021 | $3.07 Billion | +239.11% |
| 2020 | $904.20 Million | +90.35% |
| 2019 | $475.02 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Bicycle Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $182.35 Million USD |
| MoneyControl | $182.35 Million USD |
| MarketWatch | $182.35 Million USD |
| marketcap.company | $182.35 Million USD |
| Reuters | $182.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide … Read more